Lipitor

No trouble for Mohali unit, claims Ranbaxy; but what about governance?

What Ranbaxy need to understand is that, whether legally required or not, it is better to make such disclosures, which will increase transparency and boost the company's image

Ranbaxy recalls generic Lipitor in US; credibility at test?

The development will impact the company's credibility to an extent. There have been issues in the past (about compliance) and a recall suggests, corrective measures suggested by the U.S. FDA are not being implemented

Ranbaxy Q4 loss at Rs 492 cr, sees modest growth in 2013

Drug major Ranbaxy Laboratories today reported a consolidated net loss of Rs 492.44 crore for the fourth quarter ending December 31, 2012

Lipitor sales: Why Ranbaxy's Rs 2,983 cr loss won't worry investors

Ranbaxy has already provided for most of the cost related to Lipitor, which is why profit too is expected to shoot up over the next two quarters.

Ranbaxy's sweetheart Lipitor deal just turned sour. Here's why

Ranbaxy's settlement with US FDA will eat away the benefits amounting to $600 million that analysts have built in from Lipitor sales during the six months of exclusivity period.

Wrap up: Cyber space retail; time to buy infra stocks?

Confused and intimidated by the amount of news hurtling at you everyday? Well, to make your life easier, here's a quick round-up of the major local and international business and economic news events.

Ranbaxy gets prescription wrong on Lipitor, recalls 64,000 bottles in US

Ranbaxy recalled tablets of atorvastatin calcium, the generic version of Pfizer Inc's cholesterol fighter Lipitor, after a pharmacist found a 20-milligram tablet in a sealed bottle marked for 10-milligram tablets, the U.S. Food and Drug Administration (FDA) said on its website.

Teva, Ranbaxy reach settlement on drug sales with New York govt

Under the terms of the settlement, the two generic drug makers will end a 2010 agreement of not challenging each other's rights to sell certain drugs exclusively in the United States.